OCT 06, 2018 03:53 PM PDT

New Class of Drugs for Breast Cancer Therapy

WRITTEN BY: Nouran Amin

Image via Drug Target Review

Scientists at Stevens Institute of Technology have designed a new class of molecules that may hold the potential to add to the arsenal of drugs actively being created to degrade or inhibit estrogen receptors: the molecular protein which is believed to be, over the last 30 decades of research, the single most proven target in breast cancer therapy. The new class of molecules utilizes a unique biochemical mechanism that may stop or eradicate breast tumors, especially for patients with drug-resistant breast cancer or in the stages of dangerous metastasis. These developed molecules are better known as selective estrogen receptor degraders (SERDs).

“The unique benefit of our compounds is that this is a fundamentally different type of structure that was previously not known to degrade or inhibit estrogen receptors,” explains lead researcher Dr. Abhishek Sharma, “It’s not a tweak of an existing drug; it works in a completely different way.”

Due to the clinical needs and huge market potential, multiple pharmaceutical companies have invested heavily in developing SERDs. However, these companies were mainly unsuccessful in that particular drug development due to their approaches. More specifically, they focused on modifying the structure of SERDs that was originally developed decades ago.

"A schematic of a fundamentally new molecule can halt the proliferation and growth of breast cancer cells in the lab." Image Credit: Stevens Institute of Technology via Drug Target Review

The main issue facing breast cancer therapy is that many tumors no longer respond to the intended treatments, this is the essence of drug-resistance. When tumors have become drug-resistant, healthcare provides seek toxic chemotherapies to prevent cancer from relapsing and progressing. Additionally, previous SERDs are challenging to ‘package’ into pills, and large, painful injections directly into a patient’s muscles are required. Recently, clinical trial drugs have been pulled out of studies because of side effects.

Breast cancer currently affects one in eight U.S. women and tens of millions worldwide. Now, researchers are seeking ways to better combat breast cancer.

The researchers placed a core substance for estrogen receptors into a series of experimental side-chain compounds known as degrons. Once the substance has latched to the estrogen receptor, the degrons destroyed it by hijacking a cancer cell’s protein-disposal machinery and changing the direction to the receptor. However, the research team went as step further by synthesizing several variations of the novel compound which were then tested to see how they molecularly interacted with the cancer cells’ estrogen receptors. The new drugs were found to degrade the estrogen receptors and inhibit cell signaling that cue for cell growth. Additionally, they blocking the estrogen from binding and inhibited the growth and proliferation of breast cancer cells. “We consider these results to be very promising,” said Dr. Sharma. “This is a novel molecular structure, and several analogues produced excellent early activity.”

Source: Drug Target Review, ACS Medicinal Chemistry Letters

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 13, 2019
Technology
NOV 13, 2019
How Bitcoins Can Advance Medication Usage
Will futuristic concepts from the world of technology likely find a place in our medicine cabinet? Maybe! The new concept has been known as ‘cryptoph...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Comparison of Three Frontline Breast Cancer Drugs
Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 r...
NOV 13, 2019
Health & Medicine
NOV 13, 2019
A Skin Patch Might be the Most Effective Melanoma Treatment
Researchers from the Massachusetts Institute of Technology (MIT) have developed a fast-acting skin patch that effectively delivers cancer-fighting medicati...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Adderall is Almost Identical to Crystal Meth
Adderall has a reputation for giving people a feeling of euphoria, increasing energy levels and enhancing abilities to focus and concentrate. And coinciden...
NOV 13, 2019
Neuroscience
NOV 13, 2019
Can CRISPR Technology Treat Alzheimer's?
New drugs that seek to treat Alzheimer’s disease (AD) have a 99.6% failure rate. This makes it the only disease in the top 10 causes of death that ca...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Compound in Daffodils Can Help Fight Cancer
Preventing the growth of tumors presents a challenge for scientists in finding a cure to cancer. Now however, researchers from the University Libre de Brux...
Loading Comments...